Announcements - OBI Pharma 台灣浩鼎

2021.Nov.03

OBI Pharma Inc. to attend Investor Conference hosted by Masterlink Securities

2021.Oct.27

Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. of Re-election of directors and supervisors at the 2021 annual shareholders’ meeting

2021.Oct.27

Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. that the Company’s Board of Directors resolved to appoint Ms. Tessie Che as Chairperson

2021.Oct.27

Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. of Resolution to lift the non-competition restrictions for new directors

2021.Oct.27

Announcement on behalf of major subsidiary, Amaran Biotechnology, Inc. of important resolutions of the 2021 annual shareholders’ meeting

2021.Oct.27

OBI-866 ”Immunogenic/Therapeutic Glycan Compositions And Uses Thereof“ Was Granted By Taiwan Intellectual Property Office

2021.Oct.25

Application of Investigational Device Exemption for Immunohistochemistry applied to Phase II Clinical Trial of OBI-999, has been granted by FDA

2021.Oct.21

The Globo H Antibody Drug Conjugate, OBI-999, has been granted by TFDA to proceed to Phase II Human Clinical Study

2021.Oct.13

OBI filed an Application of Phase II human clinical trial for Globo-H Antibody Drug Conjugate, OBI-999, to TFDA

2021.Sep.29

OBI Filed an Application of Investigational Device Exemption (IDE) for Phase II Cohort Expansion Human Clinical Trial for Globo H Antibody Drug Conjugate, OBI-999, to FDA

News

Latest News

Events

Latest events